Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 163-182

  Yu, Debin ^a   Zhao, Mingzhi ^b   Dong, Liwei ^a   Zhao, Lu ^a   Zou, Mingwei ^c   Sun, Hetong ^d   Zhang, Mengying ^d   Liu, Hongyu ^d   Zou, Zhihua ^a  

^a JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c UNIVERSITY OF HOUSTON   (United States)

^d Beijing Building Construction Research Institute Co Ltd   (China)

Author keywords

Analog; Antiviral; IFN ; IL 28B; IL 29; Type III interferon

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; INTERFERON; INTERFERON LAMBDA; INTERFERON LAMBDA DERIVATIVE; INTERFERON TYPE III; INTERLEUKIN 28B; INTERLEUKIN 29; JANUS KINASE 1; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; PEGINTERFERON LAMBDA 6; PEGINTERFERON LAMBDA 7; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; UNCLASSIFIED DRUG; 2',5' OLIGOADENYLATE SYNTHETASE; AMINO ACID; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; ELUTION; ESCHERICHIA COLI; EXON; EXPRESSION VECTOR; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INFLUENZA A VIRUS (H3N2); MXA GENE; OAS GENE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPERNATANT; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; IC50; METABOLISM; TUMOR CELL LINE;

2',5'-OLIGOADENYLATE SYNTHETASE; AMINO ACIDS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; DRUG DESIGN; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; HEPACIVIRUS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INHIBITORY CONCENTRATION 50; INTERFERONS; MYXOVIRUS RESISTANCE PROTEINS; VIRUS REPLICATION;

EID: 84953878533     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S91455     Document Type: Article

References (55)

1. Hoffmann HH, Schneider WM, Rice CM. Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 2015;36(3):124–138.
2. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15(7):405–414.
3. Stiff A, Carson Iii W. Investigations of interferon-lambda for the treatment of cancer. J Innate Immun. 2015;7:243–250.
4. de Weerd NA, Nguyen T. The interferons and their receptors – distribution and regulation. Immunol Cell Biol. 2012;90(5):483–491.
5. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545.
6. Gibbert K, Schlaak JF, Yang D, Dittmer U. IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol. 2013; 168(5):1048–1058.
7. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96:41–101.
8. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.
9. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4(1):63–68.
10. Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2):164–171.
11. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109.
12. Zdanov A. Structural analysis of cytokines comprising the IL-10 family. Cytokine Growth Factor Rev. 2010;21(5):325–330.
13. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J Mol Biol. 2010; 404(4):650–664.
14. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem. 2009;284(31):20869–20875.
15. Blouin CM, Lamaze C. Interferon gamma receptor: the beginning of the journey. Front Immunol. 2013;4:267.
16. Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):369–376.
17. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA. Pharmacology and therapeutic potential of interferons. Pharmacol Ther. 2012; 135(1):44–53.
18. Yin Z, Dai J, Deng J, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol. 2012;189(6): 2735–2745.
19. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008;83(5):1181–1193.
20. Kotenko SV. IFN-lambdas. Curr Opin Immunol. 2011;23(5):583–590.
21. Hermant P, Michiels T. Interferon-lambda in the context of viral infections: production, response and therapeutic implications. J Innate Immun. 2014;6(5):563–574.
22. Egli A, Santer DM, O’Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect. 2014;3(7): 51.
23. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010;21(4):237–251.
24. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81(14):7749–7758.
25. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006;44(4):896–906.
26. Pott J, Mahlakoiv T, Mordstein M, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci U S A. 2011; 108(19):7944–7949.
27. Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol. 2010;84(11):5670–5677.
28. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008;4(3):e1000017.
29. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010;52(3):822–832.
30. Muir AJ, Arora S, Everson G, et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014;61(6):1238–1246.
31. Ramos EL. Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010;30(8):591–595.
32. Mahlakoiv T, Hernandez P, Gronke K, Diefenbach A, Staeheli P. Leukocyte-derived IFN-alpha/beta and epithelial IFN-lambda constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 2015;11(4):e1004782.
33. Hernandez PP, Mahlakoiv T, Yang I, et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat Immunol. 2015; 16(7):698–707.
34. Gallagher G, Megjugorac NJ, Yu RY, et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res. 2010;30(8):603–615.
35. Nice TJ, Baldridge MT, McCune BT, et al. Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity. Science. 2015;347(6219):269–273.
36. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12(9):1023–1026.
37. Koch S, Finotto S. Role of interferon-lambda in allergic asthma. J Innate Immun. 2015;7:224–230.
38. Angel J, Franco MA, Greenberg HB, Bass D. Lack of a role for type I and type II interferons in the resolution of rotavirus-induced diarrhea and infection in mice. J Interferon Cytokine Res. 1999;19(6):655–659.
39. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 2009;10(2):125–131.
40. Weber H, Valenzuela D, Lujber G, Gubler M, Weissmann C. Single amino acid changes that render human IFN-alpha 2 biologically active on mouse cells. EMBO J. 1987;6(3):591–598.
41. Spangler JB, Moraga I, Mendoza JL, Garcia KC. Insights into cytokine–receptor interactions from cytokine engineering. Annu Rev Immunol. 2015;33(1):139–167.
42. Gasteiger E, Hoogland C, Gattiker A, et al. Protein Identification and Analysis Tools on the ExPASy Server. In: Walker JM, editor: The Proteomics Protocols Handbook, Humana Press (2005). Totowa, New Jersey: Humana Press; 2005:571–607.
43. Paulson MS. Generation and quantitation of infectious hepatitis C virus derived from cell culture (HCVcc). In: Enna SJ, Williams M, editors. Current Protocols in Pharmacology. New York: John Wiley & Sons, Inc.; 2010:13B.14.11–13B.14.19.
44. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-lambda4 (IFNL4) transcript expression in human liver tissue samples. PLoS One. 2013;8(12):e84026.
45. Larocque L, Bliu A, Xu R, et al. Bioactivity determination of native and variant forms of therapeutic interferons. J Biomed Biotechnol. 2011;2011: 174615.
46. Chan HL, Ahn SH, Chang TT, et al. O115 PEGInterferon lambda for the treatment of chronic hepatitis B (CHB): a phase 2B comparison with PEGinterferon alfa in patients with HBeAg-positive disease. J Hepatol. 2014;60(1):S48.
47. Wong SS, Yuen KY. Antiviral therapy for respiratory tract infections. Respirology. 2008;13(7):950–971.
48. Jewell NA, Cline T, Mertz SE, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol. 2010;84(21):11515–11522.
49. Matzinger SR, Carroll TD, Fritts L, McChesney MB, Miller CJ. Exogenous IFN-alpha administration reduces influenza A virus replication in the lower respiratory tract of rhesus macaques. PLoS One. 2011;6(12):e29255.
50. Levin D, Schneider WM, Hoffmann HH, et al. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci Signal. 2014; 7(327): 50.
51. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996;16(7):489–499.
52. Witthoft T. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics. 2008;2(4):635–643.
53. Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. 1999;17(8):793–797.
54. Brideau-Andersen AD, Huang X, Sun SC, et al. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A. 2007; 104(20):8269–8274.
55. Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci. 2013; 34(10):534–548.